Xbrane Biopharma AB (publ) (STO: XBRANE)

Xbrane Biopharma AB Ratios and Metrics

Market cap in millions SEK. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 4, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	277	297	2,258	2,624	1,661	533
Market Cap Growth	-63.12%	-86.83%	-13.94%	58.03%	211.34%	83.60%
Enterprise Value	416	371	2,133	2,285	1,544	382
Last Close Price	0.18	10.00	82.10	104.80	74.80	34.60
PS Ratio	0.77	1.25	39.19	245.04	-	-
PB Ratio	1.06	1.74	5.31	6.08	6.44	3.35
P/TBV Ratio	1.15	1.74	5.31	6.08	8.33	5.41
EV/Sales Ratio	2.08	1.56	37.03	213.37	-	-
EV/FCF Ratio	-1.35	-	-	-	-	-
Debt / Equity Ratio	0.65	1.35	0.09	0.10	0.02	0.06
Asset Turnover	0.23	0.36	0.08	0.02	-	-
Inventory Turnover	0.44	2.59	-	-	-	-
Quick Ratio	0.49	0.42	1.02	1.84	1.68	1.10
Current Ratio	1.35	1.41	2.17	2.55	1.98	1.51
Return on Equity (ROE)	-103.07%	-108.02%	-39.34%	-53.15%	-104.60%	-155.09%
Return on Assets (ROA)	-18.63%	-27.60%	-13.84%	-19.14%	-33.74%	-38.00%
Return on Capital (ROIC)	-32.13%	-42.83%	-20.32%	-29.80%	-62.58%	-75.60%
Earnings Yield	-241.48%	-130.56%	-7.64%	-7.18%	-13.61%	-35.25%
FCF Yield	-111.90%	-139.07%	-9.10%	-9.42%	-14.59%	-28.08%
Buyback Yield / Dilution	-2952.35%	-12.26%	-8.38%	-30.25%	-61.86%	-80.09%
Total Shareholder Return	-2952.35%	-12.26%	-8.38%	-30.25%	-61.86%	-80.09%

Source: S&P Capital IQ. Standard template. Financial Sources.